MedTrace Logo

Vitis Intervention Trial in Substrate Metabolism

NCT07800988 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-09-02

No results posted yet for this study

Summary

Obesity is associated with reduced metabolic flexibility (MetFlex), the capacity to shift between carbohydrate and lipid oxidation in response to nutrient availability. Grape polyphenols (resveratrol, catechins, quercetin, epicatechin) enhance fat oxidation and mitochondrial function in laboratory and animal studies, but whole grapes, rather than purified extracts, have not been tested for acute effects on MetFlex measured directly by whole-room calorimetry paired with mitochondrial function. This study integrates whole-room indirect calorimetry with high-resolution respirometry in peripheral blood mononuclear cells (PBMCs) to determine whether whole grape polyphenols shift the postprandial respiratory exchange ratio (RER) response to a high-fat meal and alter mitochondrial respiration, and whether responses differ by adiposity phenotype (lean vs. overweight/obesity).

Conditions

  • Obesity & Overweight
  • Healthy Adult

Interventions

DIETARY_SUPPLEMENT

Freeze-Dried Whole Grape Powder

72 g, reconstituted with water, administered once per calorimeter stay, 30 minutes before the standardized high-fat test meal. Other name: whole California table grape powder.

OTHER

Placebo

Placebo Powder - 72 g matched placebo formulated to replicate the sugar, fiber, organic acid, and sensory characteristics of the grape powder without polyphenolic compounds; administered on the same schedule.

Sponsors & Collaborators

  • California Table Grapes Commission

    collaborator UNKNOWN

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Kathryn Whyte, PhD RDN · University of Alabama at Birningham

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-07-31
Completion
2027-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07800988 on ClinicalTrials.gov